Novo Nordisk is paying $240 million for global rights to a Phase 3-ready drug from Omeros that could rival immune disorder medications currently available from companies such as AstraZeneca, Novartis, ...

The future of pet care is here — smart collars, cameras and AI tools are helping owners better understand their pets’ needs.

Bookshelves often become the forgotten stepchildren of home decor — loaded with good intentions but lacking the visual punch ...

DelveInsight’s Complement 3 Glomerulopathy Market Insightsreport includes a comprehensive understanding of current treatment practices, emerging complement 3 glomerulopathy drugs, market share of ...

A new study offers hope for brain cancer patients facing memory loss from radiotherapy. By blocking a single immune receptor, scientists preserved cognition in mice without dulling the cancer-killing ...

Discover how to conquer "Pokémon GO" level 71-80 missions and unlock exclusive new rewards in 2025, enhancing your experience ...

From "Carrie" to "The Shining," we ranked every Stephen King adaptation ever made, just in time for "The Running Man" to hit ...

Essential settings and system tweaks that instantly boost gaming performance and FPS ... Properly executed, overclocking and targeted hardware investments complement pro gaming settings for maximum ...

Zaltenibart has best-in-class potential across multiple rare blood and kidney disorders and will enhance Novo Nordisk’s Rare Disease portfolio Omeros is eligible to receive 340 million US dollars in ...

Thomas Rhett has righted a honky-tonk wrong with Niall Horan by enlisting him to sing on a new version of “Old Tricks.” In a statement, Horan said he was in the studio with Bunetta when he ...